Novel artificial intelligence-enabled deep learning system to enhance adenoma detection: a prospective randomized controlled study
Source check: Source checked. Not independent scientific confirmation.
Finding: A prospective randomized study of 674 white-light colonoscopies found higher adenoma detection with the DEEP2 computer-aided detection system (37% vs 27%; 122/330 vs 93/344) and more adenomas per colonoscopy, with about four false alerts per AI exam. The result is a bounded single-center clinical detection outcome. PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
Technology: PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
- AI contribution
- PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
- Test and result
- PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
- Limitation / still unknown
- PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result. The source does not establish benefits beyond the reported evaluation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12850877/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.